S&P 500

5.304,72

0,70%

Cadastre-se gratuitamente para obter cotações em tempo real, gráficos interativos, fluxo de opções ao vivo e muito mais.

Cadastre-se

Início
Investir
Ações
EUA
NASDAQ
Millendo Therapeutics Inc (MLND)
Millendo Therapeutics Inc (MLND) Notícias

MLND

Millendo Therapeutics (MLND)

Millendo Therapeutics Inc

De:

Notícias regulamentadas

Procure um Texto:

Ordenação:

Notícias não regulamentadas

Apresentando as notícias mais relevantes sobre:NASDAQ:MLND

1 2 3 Próxima >>

Data	Hora	Fonte	Título	Código	Companhia
20/06/2023	17:54	Edgar (US Regulatory)	Statement of Changes in Beneficial Ownership (4)	NASDAQ:MLND	Millendo Therapeutics Inc
16/06/2023	17:32	Edgar (US Regulatory)	Current Report Filing (8-k)	NASDAQ:MLND	Millendo Therapeutics Inc
10/05/2023	17:25	Edgar (US Regulatory)	Quarterly Report (10-q)	NASDAQ:MLND	Millendo Therapeutics Inc
01/05/2023	17:16	Edgar (US Regulatory)	Annual Report to Security Holders (ars)	NASDAQ:MLND	Millendo Therapeutics Inc
01/05/2023	17:12	Edgar (US Regulatory)	Additional Proxy Soliciting Materials (definitive) (defa14a)	NASDAQ:MLND	Millendo Therapeutics Inc
14/02/2023	16:57	Edgar (US Regulatory)	Amended Statement of Ownership (sc 13g/a)	NASDAQ:MLND	Millendo Therapeutics Inc
14/02/2023	14:11	Edgar (US Regulatory)	Statement of Ownership (sc 13g)	NASDAQ:MLND	Millendo Therapeutics Inc
04/10/2022	09:01	Edgar (US Regulatory)	Initial Statement of Beneficial Ownership (3)	NASDAQ:MLND	Millendo Therapeutics Inc
21/06/2022	09:06	Edgar (US Regulatory)	Securities Registration: Employee Benefit Plan (s-8)	NASDAQ:MLND	Millendo Therapeutics Inc
31/05/2022	08:35	Edgar (US Regulatory)	Notice of Effectiveness (effect)	NASDAQ:MLND	Millendo Therapeutics Inc
27/05/2022	10:02	Edgar (US Regulatory)	Prospectus Filed Pursuant to Rule 424(b)(3) (424b3)	NASDAQ:MLND	Millendo Therapeutics Inc
16/05/2022	19:13	Edgar (US Regulatory)	Securities Registration Statement (simplified Form) (s-3)	NASDAQ:MLND	Millendo Therapeutics Inc
11/05/2022	16:43	Edgar (US Regulatory)	Small Company Offering and Sale of Securities Without Registration (d)	NASDAQ:MLND	Millendo Therapeutics Inc
02/05/2022	17:07	Edgar (US Regulatory)	Proxy Statement (definitive) (def 14a)	NASDAQ:MLND	Millendo Therapeutics Inc
22/04/2022	17:01	Edgar (US Regulatory)	Proxy Statement - Notice of Shareholders Meeting (preliminary) (pre 14a)	NASDAQ:MLND	Millendo Therapeutics Inc
01/04/2022	07:24	Edgar (US Regulatory)	Amended Annual Report (10-k/a)	NASDAQ:MLND	Millendo Therapeutics Inc
29/03/2022	17:59	Edgar (US Regulatory)	Annual Report (10-k)	NASDAQ:MLND	Millendo Therapeutics Inc
30/09/2021	11:47	Edgar (US Regulatory)	Amended Current Report Filing (8-k/a)	NASDAQ:MLND	Millendo Therapeutics Inc
23/07/2021	17:39	Edgar (US Regulatory)	Prospectus Filed Pursuant to Rule 424(b)(5) (424b5)	NASDAQ:MLND	Millendo Therapeutics Inc
22/06/2021	17:00	GlobeNewswire Inc.	Tempest and Millendo Announce Stockholder Approval of Merger	NASDAQ:MLND	Millendo Therapeutics Inc
11/06/2021	18:20	Edgar (US Regulatory)	Filing of Certain Prospectuses and Communications in Connection With Business Combination Transactions (425)	NASDAQ:MLND	Millendo Therapeutics Inc
10/05/2021	18:13	Edgar (US Regulatory)	Registration Statement for Securities to Be Issued in Business Combination Transactions (s-4/a)	NASDAQ:MLND	Millendo Therapeutics Inc
13/04/2021	14:50	Edgar (US Regulatory)	Securities Registration: Business Combination (s-4)	NASDAQ:MLND	Millendo Therapeutics Inc
13/04/2021	11:07	Edgar (US Regulatory)	Amended Statement of Beneficial Ownership (sc 13d/a)	NASDAQ:MLND	Millendo Therapeutics Inc
30/03/2021	08:26	TipRanks	Millendo To Merge With Tempest Therapeutics; Shares Tank	NASDAQ:MLND	Millendo Therapeutics Inc
29/03/2021	08:00	Business Wire	Tempest and Millendo Announce Proposed Merger Agreement	NASDAQ:MLND	Millendo Therapeutics Inc
05/01/2021	11:00	Business Wire	Millendo Therapeutics Provides Pipeline and Business Update	NASDAQ:MLND	Millendo Therapeutics Inc
09/11/2020	10:30	Business Wire	Millendo Therapeutics Reports Third Quarter 2020 Operating and Financial Results	NASDAQ:MLND	Millendo Therapeutics Inc
24/09/2020	09:30	Business Wire	Millendo Therapeutics Announces Initiation of First-in-Human Clinical Trial of MLE-301, a Selective NK3R Antagonist	NASDAQ:MLND	Millendo Therapeutics Inc
03/09/2020	09:30	Business Wire	Millendo Therapeutics to Participate in September Investor Conferences	NASDAQ:MLND	Millendo Therapeutics Inc